The Pediatric Onco-Hematology Clinical Research Unit, headed by Antonio Pérez-Martínez, comprises a multidisciplinary team of physicians, geneticists, biologists, biochemists, and bioinformaticians, who, for the past decade, have carried out projects ranging from knowledge generation to direct clinical application through the development of clinical trials. Our research, which is mostly funded by Fundación Cris Contra el Cáncer, focuses on the design of therapies applied to paediatric oncology, infectious diseases, and paediatric transplantation. Briefly, our research interests include: 1) the use of haematopoietic stem cell transplantation as a platform for cell therapy; 2) the improvement of human stem cell progenitors transplantation in children; 3) cell therapy with memory T lymphocytes as adoptive immunotherapy; and 4) the use of both activated and memory-like NK cells and CART-T cells in paediatric oncology. Together with this, we led several projects aimed at studying the efficacy and feasibility of cell therapy against infectious diseases. Finally, we are also working on the induction of immunological tolerance in solid organ transplantation by inducing mixed haematopoietic chimera through cell therapy. We maintain a strong commitment to patients and to improving their quality of life, having a direct impact on society’s well-being. In this sense, we have several active academic clinical trials and collaborations with industry, with the objective of developing new and more effective therapies with fewer side effects.
Investigadores Científicos
- Víctor Galán
Investigador Clínico I
- Carmen Mestre
Becarios Post-doctorales
- Cristina Aguirre
- Alfonso Alba
- Halin Bareke
- Elisa Pilar Izquierdo
- Adriana Mañas
- Jordi Minguillón
- Andrés París
- Odelaisy León Triana
Becarios Pre-Doctorales
- Karima Al Akioui
- Álvaro Blázquez
- Laura Clares
- María Octavia de Santisteban
- Esther Díaz Maroto
- Mikel Fernández
- Sara Fernández
- Beatriz García
- Adrián Ibáñez
- Marta Ibáñez
- Beatriz Madroñal
- Alicia Martín
- Andrea Matesanz
- Antonio Jesús Muñoz
- Sara Naharro
- Alfonso Navarro
- Beatriz Ruz
- Cristina Smith
- Claudia Suanzes
- Clara Venegas
Técnicos de Laboratorio
- Estefania Ayala
- Lidia Pertiñez
- Natalia Riestra
Publicaciones
- (2024). PRDX6 contributes to selenocysteine metabolism and ferroptosis resistance. Mol Cell (in press). Publicación CNIO.
- (2024). Advances in the approaches used to repurpose drugs for neuroblastoma. Expert Opin Drug Discov 19, 1309-1319. Publicación CNIO.
- (2024). Formin-like 1β phosphorylation at S1086 is necessary for secretory polarized traffic of exosomes at the immune synapse in Jurkat T lymphocytes. Elife (in press). Publicación CNIO.
- (2024). NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells. Front Inmmunol 14, . Publicación CNIO.
- (2024). BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors. Sci Rep 14, 13133. Publicación CNIO.
- (2024). Safety and Efficacy of High-Dose Memory CD45RO+ Donor Lymphocyte Infusion in Pediatric Recipients after Hematopoietic Stem Cell Transplantation. Cytotherapy 26, 1458-1464. Publicación CNIO.
- (2024). Alternative production of pro-death Bax∆2 protein via ribosomal frameshift in Alzheimer’s disease. Sci Rep 14, 27288. Publicación CNIO.
- (2024). The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19. iScience 28, 111698. Publicación CNIO.
- (2024). Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients. J Clin Med 13, 6294. Publicación CNIO.
- (2023). Helios as a potential biomarker in systemic lupus erythematosus and new therapies based on immunosuppressive cells. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 25, 452. Publicación CNIO.